A new strategy for the development of monoclonal antibodies for the determination of human procalcitonin in serum samples

Electrochemical immunosensor based on hollow Pt@Cu2O as a signal label for dual-mode detection of procalcitonin

As a reliable biomarker to evaluate the severity of sepsis, sensitive and accurate detection of procalcitonin (PCT) is essential. In this study, a dual-mode electrochemical immunosensor based on Au/ZIF-8 as substrate and Pt@Cu2O as signal label was constructed for the detection of PCT. By loading Au nanoparticles onto rhombic dodecahedral ZIF-8, the substrate (Au/ZIF-8) has large specific surface area and can immobilize antibody (Ab1) by Au-N bonds. Meanwhile, hollow Pt@Cu2O nanocomposite with excellent peroxidase-like activity and electrocatalytic activity were synthesized as signal label. In the process of electrochemical testing, Pt@Cu2O catalyzed the reduction of hydrogen peroxide (H2O2) and further promotes the oxidation of hydroquinone (HQ) to achieve the synergistic amplification of electrochemical signals. The proposed immunosensor detected PCT by amperometric i-t and differential pulse voltammetry (DPV) tests with a good linear response and low limit of detection (i-t: 0.70 fg/mL and DPV: 0.40 fg/mL) in the range of 10 fg/mL∼100 ng/mL. The immunosensor exhibited excellent sensitivity and accuracy, indicating the potential application of this method for PCT detection.

3D carbonized wood-based integrated electrochemical immunosensor for ultrasensitive detection of procalcitonin antigen

This work presents a novel 3D carbonized wood-based integrated electrochemical immunosensor for ultrasensitive detection of procalcitonin (PCT) antigen at picogram level, achieving a wide linear detection range for PCT concentrations range from 0.05 to 90 pg mL^-1 with a low detection limit of 0.014 pg mL^-1 (S/N = 3), outperforming the previous reports. 3D carbonized wood as a new immunosensor matrix is used for electrochemical PCT biosensing, improving the stability of electrode and overcoming the disadvantages of traditional glassy carbon electrode (GCE). It obtained an excellent detection result, due to it has abundant mutual crisscross microchannels that promote the reactants and electrons transfer, greatly amplify the current signal. This novel sandwich-type electrochemical immunosensor is composed of 3D carbonized wood, carboxylic multi-walled carbon nanotube (cMWCNT), Au@Co₃O₄ core-shell nanosphere and Au/single layer nitrogen-doped graphene (Au/SL-NG), when it is applied for PCT detection in real clinical samples, it exhibits high accuracy same as enzyme-linked immunosorbent assay (ELISA) method.

Electrochemical Immunosensors for Quantification of Procalcitonin: Progress and Prospects

Human procalcitonin (PCT) is a peptide precursor of the calcium-regulating hormone calcitonin. Traditionally, PCT has been used as a biomarker for severe bacterial infections and sepsis. It has also been recently identified as a potential marker for COVID-19. Normally, serum PCT is intracellularly cleaved to calcitonin, which lowers the levels of PCT (<0.01 ng/mL). In severe infectious diseases and sepsis, serum PCT levels increase above 100 ng/mL in response to pro-inflammatory stimulation. Development of sensors for specific quantification of PCT has resulted in considerable improvement in the sensitivity, linear range and rapid response. Among the various sensing strategies, electrochemical platforms have been extensively investigated owing to their cost-effectiveness, ease of fabrication and portability. Sandwich-type electrochemical immunoassays based on the specific antigen–antibody interactions with an electrochemical transducer and use of nanointerfaces has augmented the electrochemical response of the sensors towards PCT. Identification of a superior combination of electrode material and nanointerface, and translation of the sensing platform into flexible and disposable substrates are under active investigation towards development of a point-of-care device for PCT detection. This review provides an overview of the existing detection strategies and limitations of PCT electrochemical immunosensors, and the emerging directions to address these lacunae.

Development of magnetic particle-based chemiluminescence immunoassay for measurement of human procalcitonin in serum

BACKGROUND

Serum procalcitonin (PCT) has been recognized as a primary biomarker in bacterial infections, and monitoring its concentration could help to evaluate the prognosis of sepsis and guide the antibiotic administration. We aimed to establish a fast and accurate immunoassay for PCT quantitation.

METHODS

Our newly developed monoclonal antibodies (mAbs) against human PCT were preliminarily evaluated by enzyme-linked immunosorbent assay and then used to develop a chemiluminescence enzyme immunoassay (CLEIA). The proposed CLEIA was assessed in analytical performance and applied to measurement of serum PCT.

RESULTS

mAb 2D3 and mAb 8F6 were selected as capture and detection antibody respectively, due to the highest sensitivity for PCT detection with no cross reaction to calcitonin gene-related peptides. The proposed CLEIA based on mAb pair of 2D3/8F6-AP was characterized for a working range from 0.03 to 100 μg/L. An excellent correlation was observed between our proposed assay and the VIDAS BRAHMS PCT assay (r: 0.9825).

CONCLUSION

Our newly developed mAbs and CLEIA can serve as important diagnostic tools for measurement of human PCT in serum.

Magnetic Bead-Based Electrochemical Immunoassays On-Drop and On-Chip for Procalcitonin Determination: Disposable Tools for Clinical Sepsis Diagnosis

Procalcitonin (PCT) is a known protein biomarker clinically used for the early stages of sepsis diagnosis and therapy guidance. For its reliable determination, sandwich format magnetic bead-based immunoassays with two different electrochemical detection approaches are described: (i) disposable screen-printed carbon electrodes (SPE-C, on-drop detection); (ii) electro-kinetically driven microfluidic chips with integrated Au electrodes (EMC-Au, on-chip detection). Both approaches exhibited enough sensitivity (limit of detection (LOD) of 0.1 and 0.04 ng mL⁻¹ for SPE-C and EMC-Au, respectively; cutoff 0.5 ng mL⁻¹), an adequate working range for the clinically relevant concentrations (0.5–1000 and 0.1–20 ng mL⁻¹ for SPE-C and EMC-Au, respectively), and good precision (RSD < 9%), using low sample volumes (25 µL) with total assay times less than 20 min. The suitability of both approaches was successfully demonstrated by the analysis of human serum and plasma samples, for which good recoveries were obtained (89–120%). Furthermore, the EMC-Au approach enabled the easy automation of the process, constituting a reliable alternative diagnostic tool for on-site/bed-site clinical analysis.

Polymer-Based Micromotor Fluorescence Immunoassay for On-the-Move Sensitive Procalcitonin Determination in Very Low Birth Weight Infants' Plasma

A new fluorescence micromotor-based immunoassay (FMIm) has been developed for procalcitonin (PCT) determination as an early sepsis diagnostic analytical tool. The micromotors combine the high binding capacity of the specific antibodies onto their polymeric polypyrrole outer layer (PPy layer), with their magnetic guidance (Ni layer) and self-propulsion by catalytic generation of oxygen bubbles (PtNP inner layer) to actively recognize the PCT antigen. This FMIm allowed a sensitive (LOD = 0.07 ng mL^-1) and direct PCT determination in clinical samples from very low-birth-weight infants (VLBWI) with sepsis suspicion, using small volumes of sample (25 μL) in a clinically relevant range of concentrations (0.5-150 ng mL^-1). The good agreement between PCT levels obtained by our micromotor-based method and routine immunofluorescence hospital determination demonstrates the feasibility for the analysis in VLBWI samples and its potential as a point-of-care diagnostic tool for sepsis.

In Situ Growth of CuWO4 Nanospheres over Graphene Oxide for Photoelectrochemical (PEC) Immunosensing of Clinical Biomarker

Procalcitonin (PCT) protein has recently been identified as a clinical marker for bacterial infections based on its better sepsis sensitivity. Thus, an increased level of PCT could be linked with disease diagnosis and therapeutics. In this study, we describe the construction of the photoelectrochemical (PEC) PCT immunosensing platform based on it situ grown photo-active CuWO₄ nanospheres over reduced graphene oxide layers (CuWO₄@rGO). The in situ growth strategy enabled the formation of small nanospheres (diameter of 200 nm), primarily composed of tiny self-assembled CuWO₄ nanoparticles (2–5 nm). The synergic coupling of CuWO₄ with rGO layers constructed an excellent photo-active heterojunction for photoelectrochemical (PEC) sensing. The platform was then considered for electrocatalytic (EC) mechanism-based detection of PCT, where inhibition of the photocatalytic oxidation signal of ascorbic acid (AA), subsequent to the antibody–antigen interaction, was recorded as the primary signal response. This inhibition detection approach enabled sensitive detection of PCT in a concentration range of 10 pg·mL⁻¹ to 50 ng.mL⁻¹ with signal sensitivity achievable up to 0.15 pg·mL⁻¹. The proposed PEC hybrid (CuWO₄@rGO) could further be engineered to detect other clinically important species.

Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay

Procalcitonin (PCT) is well established as a highly specific biomarker for the detection of bacterial infections and sepsis. However, the currently available diagnostic tests are not able to detect very low or very early increases of PCT or even baseline levels in healthy individuals or patients with non-bacterial infections. In order to be able to detect these very low concentrations of PCT, a sandwich immunoassay was developed using high sensitivity Single Molecule Array technology (Simoa). The assay was thoroughly validated and applied to analyze human cerebrospinal fluid (CSF) and serum samples from patients with bacterial or viral meningitis as well as CSF, serum, and K2 EDTA plasma from healthy control subjects. A 50-fold increase in sensitivity compared to the current gold standard assays was achieved, which was sensitive enough for the detection of baseline PCT levels. Both serum and CSF showed significantly elevated PCT levels in patients with bacterial meningitis compared to patients with viral meningitis and the healthy control group. Procalcitonin concentration levels for patients with viral meningitis and the control group could be measured, but were not significantly different. The determination of PCT in the low pg·mL⁻¹ range could help to improve the monitoring of bacterial infectious diseases, as PCT level changes could be detected earlier.

A new ELISA for the quantification of equine procalcitonin in plasma as potential inflammation biomarker in horses

In human medicine, procalcitonin (PCT) is a very common and well-established biomarker for sepsis. Even though sepsis is also a leading cause of death in foals and adult horses, up to now, no data about the role of equine PCT in septic horses has been available. Based on monoclonal antibodies targeted against human PCT, we report here the development of a sandwich ELISA for the quantification of equine PCT in equine plasma samples. The ELISA was characterized for intra- and interassay variance and a working range from 25 to 1,000 ng mL(-1) was defined as within this range; both intra- and interassay variances were below 15 %. The target recovery ranged between 73 and 106 %. The ELISA was used to determine the equine PCT concentration in 24 healthy and 5 septic horses to show the potential for clinical evaluation of equine PCT. Significantly different (P = 0.0006) mean equine PCT concentrations were found for the healthy control group and the sepsis group (47 and 8,450 ng mL(-1)).